Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe - PubMed (original) (raw)
. 2001 Feb 9;276(6):4236-44.
doi: 10.1074/jbc.M003798200. Epub 2000 Oct 24.
Affiliations
- PMID: 11050076
- DOI: 10.1074/jbc.M003798200
Free article
Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe
X Q Ding et al. J Biol Chem. 2001.
Free article
Abstract
Affinity labeling is a powerful tool to establish spatial approximations between photolabile residues within a ligand and its receptor. Here, we have utilized a cholecystokinin (CCK) analogue with a photolabile benzoylphenylalanine (Bpa) sited in position 24, adjacent to the pharmacophoric domain of this hormone (positions 27-33). This probe was a fully efficacious agonist that bound to the CCK receptor saturably and with high affinity (K(i) = 8.9 +/- 1.1 nm). It covalently labeled the CCK receptor either within the amino terminus (between Asn(10) and Lys(37)) or within the third extracellular loop (Glu(345)), as demonstrated by proteolytic peptide mapping, deglycosylation, micropurification, and Edman degradation sequencing. Truncation of the receptor to eliminate residues 1-30 had no detrimental effect on CCK binding, stimulated signaling, or affinity labeling through a residue within the pharmacophore (Bpa(29)) but resulted in elimination of the covalent attachment of the Bpa(24) probe to the receptor. Thus, the distal amino terminus of the CCK receptor resides above the docked ligand, compressing the portion of the peptide extending beyond its pharmacophore toward the receptor core. Exposure of wild type and truncated receptor constructs to extracellular trypsin damaged the truncated construct but not the wild type receptor, suggesting that this domain also may play a protective role. Use of these additional insights into molecular approximations provided key constraints for molecular modeling of the peptide-receptor complex, supporting the counterclockwise organization of the transmembrane helical domains.
Similar articles
- Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
Dong M, Liu G, Pinon DI, Miller LJ. Dong M, et al. Biochemistry. 2005 May 3;44(17):6693-700. doi: 10.1021/bi050130q. Biochemistry. 2005. PMID: 15850403 - Molecular basis of agonist binding to the type A cholecystokinin receptor.
Miller LJ, Lybrand TP. Miller LJ, et al. Pharmacol Toxicol. 2002 Dec;91(6):282-5. doi: 10.1034/j.1600-0773.2002.910603.x. Pharmacol Toxicol. 2002. PMID: 12688369 Review. - Characterization of the type A cholecystokinin receptor hormone-binding domain: use of contrasting and complementary methodologies.
Ding XQ, Miller LJ. Ding XQ, et al. Peptides. 2001 Aug;22(8):1223-8. doi: 10.1016/s0196-9781(01)00445-4. Peptides. 2001. PMID: 11457514 Review.
Cited by
- Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.
Dong M, Miller LJ. Dong M, et al. Peptides. 2013 Aug;46:143-9. doi: 10.1016/j.peptides.2013.06.007. Epub 2013 Jun 14. Peptides. 2013. PMID: 23770253 Free PMC article. - Sensitivity of cholecystokinin receptors to membrane cholesterol content.
Desai AJ, Miller LJ. Desai AJ, et al. Front Endocrinol (Lausanne). 2012 Oct 18;3:123. doi: 10.3389/fendo.2012.00123. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 23087674 Free PMC article. - Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.
Dong M, Lam PC, Pinon DI, Abagyan R, Miller LJ. Dong M, et al. Biochemistry. 2009 Jun 16;48(23):5303-12. doi: 10.1021/bi9004705. Biochemistry. 2009. PMID: 19441839 Free PMC article. - Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.
Desai AJ, Lam PC, Orry A, Abagyan R, Christopoulos A, Sexton PM, Miller LJ. Desai AJ, et al. J Med Chem. 2015 Dec 24;58(24):9562-77. doi: 10.1021/acs.jmedchem.5b01110. Epub 2015 Dec 10. J Med Chem. 2015. PMID: 26654202 Free PMC article. - Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor.
Gao F, Sexton PM, Christopoulos A, Miller LJ. Gao F, et al. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4401-4. doi: 10.1016/j.bmcl.2008.06.053. Epub 2008 Jun 20. Bioorg Med Chem Lett. 2008. PMID: 18621527 Free PMC article.